Travere Therapeutics Reports Strong Q1 Results and Major FDA Approval for FILSPARI in FSGS
Summary
Travere Therapeutics announced strong first-quarter financial results, including a 64% increase in product sales and a swing to non-GAAP net income, alongside a pivotal FDA approval for FILSPARI in FSGS, significantly expanding its market opportunity.
Key Events
-
FDA Approval for FILSPARI in FSGS
The U.S. Food and Drug Administration (FDA) approved FILSPARI on April 13, 2026, to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. This approval expands the total addressable FILSPARI patient population in the U.S. to more than 100,000 across IgAN and FSGS.
-
Strong Q1 Financial Performance
U.S. net product sales for the first quarter of 2026 reached $124.5 million, a 64% increase year-over-year. The company reported a non-GAAP adjusted net income of $4.1 million, or $0.05 per basic share, compared to a net loss in the prior year.
-
FILSPARI IgAN Continues Strong Growth
FILSPARI achieved record demand with 993 new patient start forms (PSFs) for IgAN in the U.S. during the first quarter, and U.S. net product sales grew 88% year-over-year to $105.2 million.
-
Pegtibatinase Phase 3 Study Restarted
Enrollment activities in the pivotal Phase 3 HARMONY Study of pegtibatinase for classical Homocystinuria (HCU) have restarted, with the first new patient dosed in April 2026. Topline data is anticipated in the second half of 2027.
Analysis
Travere Therapeutics delivered a strong first quarter, highlighted by a significant FDA approval for its flagship drug, FILSPARI, in Focal Segmental Glomerulosclerosis (FSGS). This approval dramatically expands the total addressable patient population for FILSPARI to over 100,000 across IgAN and FSGS, positioning the company for substantial long-term growth. The financial results were robust, with product sales increasing 64% year-over-year and the company achieving non-GAAP adjusted net income, a notable improvement from a loss in the prior year. This positive operational news comes as the stock is trading near its 52-week high, reflecting strong market sentiment. However, investors should note the concurrent insider selling activity, which presents a contrasting signal despite the strong company performance.
At the time of this filing, TVTX was trading at $43.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $13.88 to $45.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.